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Abstract
In the previous issue of Arthritis Research & Therapy data are 
presented showing that circulating immune complexes containing 
citrullinated fibrin(ogen) are present in anti-citrullinated protein 
antibody-positive rheumatoid arthritis patients, and that such 
immune complexes co-localize with complement factor C3 in the 
rheumatoid synovium. These results corroborate the idea that 
citrullination is intimately involved in the pathophysiology of 
rheumatoid arthritis and complete our model (the rheumatoid arthritis 
cycle) for the development and chronic nature of this disease.
Rheumatoid arthritis (RA) is a chronic, progressive, inflam­
matory autoimmune disease characterized by the presence of 
several autoantibodies. Among the autoantibodies detected 
in RA, only rheumatoid factor and anti-citrullinated protein/ 
peptide antibodies (ACPAs) are considered clinically useful. 
Both the measurement of antibodies directed against cyclic 
citrullinated peptides (CCP) and rheumatoid factor determi­
nations are commonly used in daily clinical practice. Because 
of the extreme specificity of ACPAs, we and others have 
previously proposed that these antibodies might be involved 
in the pathophysiology of RA. Since then, experimental 
evidence supporting several pieces of the RA cycle (Figure 1) 
has been obtained. In the previous issue of A rthritis  Research 
& Therapy, Zhao and colleagues [1] fill in one of the last gaps 
in our knowledge on the cycle of events leading to RA. The 
authors utilized complement C1q to capture immune 
complexes (ICs) from plasma and protein G  to capture ICs 
from pannus tissue derived from human RA and control 
patients, and demonstrated that ICs containing citrullinated 
fibrin(ogen) were present in about 50% of anti-CCP-positive 
patients. They were not detectable in RA patients lacking 
these antibodies and control patients with other autoimmune 
diseases. In the rheumatoid synovium, fibrin(ogen)-containing 
ICs co-localize with complement factor C3, suggesting that 
they contribute to synovitis in a subset of patients.
There are many citrullinated proteins in the inflamed RA 
synovium [2] - for example, vimentin, histones, collagen types
I and II, and a-enolase - but citrullinated fibrin(ogen) is 
certainly one of the most abundant and important antigens 
[3]. The fact that only half of the anti-CCP(+) patients 
possess ICs with citrullinated fibrin(ogen), however, 
illustrates the heterogeneity in the ACPA repertoire. It is likely 
that ICs in the other anti-CCP(+) patients contain one or 
more of the other citrullinated antigens. The important study 
of Zhao and collaborators cements into place one of the last 
pieces of the RA cycle, as depicted in Figure 1 and 
discussed by us and others previously [4-6]. In this model for 
the development and chronicity of RA at least five steps can 
be distinguished.
Step 1
An in itself innocent inflammation of the joint or other tissue in 
the body leads to infiltration of inflammatory cells (granulo­
cytes, monocytes, lymphocytes). In normal situations many of 
the infiltrating cells will die via apoptosis and will be cleared 
(removed) by phagocytes. However, when there is massive 
apoptosis, for example due to a toxicant or infection, or a 
(genetic) defect in the clearance system, some apoptotic 
cells may become necrotic. Granulocytes and monocytes, 
and macrophages emerging from monocyte differentiation, 
contain citrullinating peptidylarginine deiminase (PAD) 
enzymes. These enzymes are activated by the elevation of 
cytosolic Ca2+-concentrations, for example when cells under­
go apoptosis.
Step 2
When the dying inflammatory cells are not cleared properly 
and become necrotic, they release the intracellular citrullinated 
proteins (for example, histones, vimentin) and the activated 
PAD enzymes. These enzymes, PAD2 and/or PAD4, can then 
citrullinate extracellular synovial proteins like fibrin(ogen).
ACPA = anti-citrullinated protein/peptide antibody; CCP = cyclic citrullinated peptide; IC = immune complex; PAD = peptidylarginine deiminase; 
RA = rheumatoid arthritis.
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Figure 1
The rheumatoid arthritis (RA) cycle. Model for the role of protein citrullination in the pathophysiology of RA. The various aspects of the five major steps 
are depicted. Step 1, entry and death of inflammatory cells in the synovium; step 2, peptidylarginine deiminase (PAD) activation and protein 
citrullination; step 3, immune response to citrullinated antigens; step 4, formation of citrullinated immune complexes and their effects; step 5, 
recruitment of new inflammatory cells. ACPA, anti-citrullinated protein/peptide antibody.
However, the mere presence of citrullinated proteins will not 
necessarily lead to chronic inflammation because in 99%  of 
individuals these citrullinated proteins are degraded without a 
(humoral) reaction of the immune system [4]. The presence of 
a large number of citrullinated proteins in the inflamed 
synovium has been shown by several groups (for a recent 
review, see [2]).
Step 3
In those individuals who are able to present citrullinated 
fragments of proteins to T cells via certain HLA molecules, an 
immune response to citrullinated antigens might be genera­
ted, resulting in the production of high affinity IgG ACPAs [7]. 
Activation of autoreactive B  cells may occur locally in the 
(inflamed) joint, but may also occur in other inflamed tissues. 
Via the circulation, these ACPAs or the plasma cells 
producing them will ultimately enter the joint, for example 
when a local inflammation occurs or as a result of immune 
complex-facilitated vascular leakage [6]. Irrespective of the 
site of B  cell activation, there is experimental evidence that 
ACPAs are produced in RA joints and may mediate tissue 
injury [2,8].
Recent support for a mechanism as described above has 
been provided by Hill and collaborators [9]. They showed that 
citrullinated fibrinogen is able to induce arthritis in DR4-IE 
transgenic mice. T cell epitope scanning and antibody
microarray analysis identified a unique pattern of citrulline- 
specific reactivity that was not found in DR4-IE transgenic 
mice immunized with unmodified fibrinogen or in wild-type 
C57BL/6 mice immunized with citrullinated fibrinogen. These 
observations directly implicate citrullinated fibrinogen as 
arthritogenic in the context of RA-associated major histo­
compatibility (MHC) class II molecules [9]. It is quite likely 
that this also holds for other citrullinated antigens, such as 
vimentin and histones.
Step 4
After their production in/entry into the inflamed synovium, 
ACPAs can react with the abundantly available citrullinated 
antigens. The paper of Zhao and collaborators [1] is the first 
to show the presence of such ICs in circulating plasma as 
well as in the inflamed synovium. These ICs stimulate the 
inflammatory process by activation of the complement system 
and further recruitment and activation of granulocytes, 
monocytes, and macrophages via both complement receptor- 
and Fcy receptor-dependent pathways. In this way, ACPAs 
contribute to the perpetuation of joint inflammation and to the 
chronicity and severity of RA.
Step 5
New monocytes and granulocytes will enter the synovium, 
where they will be activated, subsequently die and release 
another load of activated PAD enzymes. A new round of
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citrullinated antigens and ACPA production will take place, 
leading to a new flare of inflammation. It has been noted that 
novel IgM-producing B cells are continuously recruited to the 
inflamed RA joint, demonstrating that the ACPA response is 
continuously reactivated during the course of arthritis [10].
The continuation of this vicious circle for years, eventually 
accompanied by fresh traumas or environmental events that 
stimulate inflammation, will ultimately lead to a chronic 
inflammation that manifests as the disease we know as RA.
The paper of Zhao and collaborators proves one of the last 
suppositions of the RA cycle. This model will allow us to 
design new strategies to interfere with the chronic cycle of 
events in the inflamed joints, which may ultimately lead to the 
development of new and more specific therapies for RA.
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